← Leaderboards
Christopher D Lao
University Of Michigan At Ann Arbor
$735,716
Attributed
$735,716
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $156.1K · FY2005–10$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$735,716 · 4
By mechanism
K07$688,500 · 1
M01$47,216 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Imad Shureiqi$13,361,753
- Rohit N. Kulkarni$31,021,904
- Catherine A Spino$34,285,809
- Arul M Chinnaiyan$35,112,976
- Jennifer Yeung$240,163
Others in their field
Top investigators on “Curcumin”
- Ah-Ng Tony Kong · University Of Illinois At Chicago$6,448,812
- Kristin Aillon · Midwest Research Institute$4,931,007
- Rohit Loomba · Indiana University Indianapolis$4,338,590
- Gregory M Cole · Va Greater Los Angeles Healthcare System$4,323,315
- Maya Koronyo-Hamaoui · Neurovision Imaging, Llc$4,232,874
- Chongzhao Ran · Massachusetts General Hospital$4,170,463
Research focus
CurcuminDoseCountryAngiogenesisDinoprostoneArachidonic AcidsAnimalsBenign Melanocytic NevusBinding (Molecular Function)ApoptoticAnimal ModelBiopsyBreslow ThicknessCancer CellCarcinogenesisAwardCellsCell SurvivalChemopreventionChemopreventive AgentClinicClinical TrialsArachidonate 12-LipoxygenaseDysplastic Nevus
Grant awards (8)
Development of a Melanoma Chemoprevention Model$137,700
K07 · FY2010 · CA · contact PI
Development of a Melanoma Chemoprevention Model$137,700
K07 · FY2009 · CA · contact PI
Development of a Melanoma Chemoprevention Model$137,700
K07 · FY2008 · CA · contact PI
Development of a Melanoma Chemoprevention Model$137,700
K07 · FY2007 · CA · contact PI
Development of a Melanoma Chemoprevention Model$137,700
K07 · FY2006 · CA · contact PI
PHASE I SINGLE-DOSE SAFETY AND PHARMACOKINETICS CLINICAL STUDY OF RESVERATROL$18,395
M01 · FY2006 · RR · contact PI
PHASE I SINGLE-DOSE SAFETY AND PHARMACOKINETICS CLINICAL STUDY OF RESVERATROL$27,791
M01 · FY2005 · RR
FEASIBILITY OF BARRETT?S ESOPHAGUS CHEMOPREV THROUGH EVAL OF ESOPHAGEAL RESECT$1,030
M01 · FY2005 · RR